Prostate Cancer Prospective Cohort
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00937586|
Recruitment Status : Active, not recruiting
First Posted : July 13, 2009
Last Update Posted : November 25, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease|
DNA will be isolated from each person and then studied for the presence of certain genes that may increase the chance of developing prostate cancer. Certain genes will also be studied in patients with known prostate cancer to determine if they increase the chance of cancer spreading to other parts of the body and decrease one's chance of being cured. Small differences in genes can slightly affect their ability to function. While these differences are normal, they may influence the way the cancer responds to therapy. An understanding of which genes increase (or decrease) the chance of being cured of a disease, such as prostate cancer, will improve our ability to take care of patients more effectively.
A second purpose of this study is to collect blood and cancer tissue for future studies. While the small differences in genes may be the best marker of bad cancer, it is also possible that proteins in blood or tumor may be a better marker.
|Study Type :||Observational|
|Actual Enrollment :||1937 participants|
|Official Title:||Prostate Cancer Prospective Cohort|
|Study Start Date :||May 2000|
|Estimated Primary Completion Date :||June 2025|
|Estimated Study Completion Date :||June 2025|
Newly diagnosed patients
Patients with newly diagnosed prostate cancer.
- Ability to recognize increased risk of metastatic prostate cancer based on specific genetic polymorphisms. [ Time Frame: At the time of prostate cancer diagnosis ]
- Ability to predict risk for treatment failure based on analysis of specific polymorphisms. [ Time Frame: At the time of prostate cancer diagnosis ]
Biospecimen Retention: Samples Without DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 100 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||Male|
|Accepts Healthy Volunteers:||Yes|
|Sampling Method:||Non-Probability Sample|
- Newly diagnosed patients: 1. newly diagnosis of prostate cancer 2. untreated except for neoadjuvant systemic therapy.
- Newly diagnosed patients: 1. inability to give informed consent
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00937586
|United States, Missouri|
|Washington University School of Medicine|
|Saint Louis, Missouri, United States, 63110|
|Principal Investigator:||Bettina Drake, PhD||Washington University School of Medicine|
|Responsible Party:||Washington University School of Medicine|
|Other Study ID Numbers:||
R01CA112028 ( U.S. NIH Grant/Contract )
|First Posted:||July 13, 2009 Key Record Dates|
|Last Update Posted:||November 25, 2022|
|Last Verified:||November 2022|
Metastatic Prostate Cancer
Prostate Cancer Risk Assessment
Genital Neoplasms, Male
Neoplasms by Site